Financial Performance - BMO's adjusted EPS increased by 26% from $9.68 in F2024 to $12.16 in F2025[9] - The adjusted return on equity improved by 150 bps, rising from 9.8% in F2024 to 11.3% in F2025[9] - Adjusted PPPT increased by 14%, from $13.3 billion in F2024 to $15.2 billion in F2025[9] - Adjusted net income for Q4 2025 increased by 63%, excluding $123 million amortization of acquisition-related intangible assets and $102 million goodwill write-down[33] - Adjusted revenue for Q4 2025 increased by 12%, driven by broad-based growth across all operating segments and strong fee growth in Wealth Management and Capital Markets[33] Business Segment Performance - Canadian Personal & Commercial Banking revenue increased by 7%, from $11.4 billion in F2024 to $12.3 billion in F2025[15] - Wealth and Asset Management revenue increased by 15%, from $4.6 billion in F2024 to $5.3 billion in F2025[12] - Investment and Corporate Banking revenue increased by 14%, from $6.5 billion in F2024 to $7.4 billion in F2025[14] - U S Banking adjusted PPPT increased by 30% year-over-year[18] Risk and Capital Management - The PCL impaired loans ratio decreased by 230 bps[9] - The CET1 ratio stands at 13.3%[9]

Denali's TransportVehicle (TV) Platform - Denali's TransportVehicle (TV) platform enables systemic delivery of biologics to the brain and other hard-to-target tissues[14, 25] - The company's TransportVehicle (TV) is the most clinically validated BBB technology with over 11,000 doses administered[61] - Denali's TransportVehicle (TV) platform has demonstrated best-in-class properties for brain uptake, modularity, safety, and architecture[55] Near-Term Launch Opportunities - Denali plans to launch tividenofusp alfa (DNL310) in 2026 and DNL126 in 2027, which could capture a $1B+ market opportunity[15] - Tividenofusp alfa has a PDUFA target action date of April 5, 2026[168] - Denali is targeting all ~2,000 MPS II patients worldwide in commercially accessible geographies[246] Pipeline and Therapeutic Areas - Denali has a broad clinical-stage pipeline across high-value therapeutic areas, including Alzheimer's disease and Parkinson's disease[16] - The company estimates a total addressable market (TAM) of >$5B for the ETV franchise[63] - Denali estimates a >$5B market potential for BBB-enabled AD therapeutics[68] Financial and Strategic Execution - Denali is well-capitalized and focused on efficient capital allocation and execution timelines for long-term value creation[17] - The company has secured $275M in potential total funding through a royalty financing agreement with Royalty Pharma[443] - Denali projects COGS <20% of revenue due to efficient processes[407]

Edwards Lifesciences 2025 Investor Conference 2025 Investor Conference Mark Wilterding Cautionary Statement Presentations and comments made today by management of Edwards Lifesciences Corporation (the "Company") will include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can sometimes be identified by the use of words, such as "may," "will," "should," ...

Paulo CASTELLARI, CEO Abel MARTINS-ALEXANDRE, CFO 4 th December, 2025 Disclaimer Certain information contained in this presentation including any information on Eramet's plans or future financial or operating performance and any other statements that express management's expectations or estimates of future performance, constitute forward-looking statements. Such statements are based on a number of estimates and assumptions that, while considered reasonable by management at the time, are subject to significa ...

Residential Kitchen Majority Sale Announcement December 4, 2025 1 Cautionary statements Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of these forward-looking statements can be identified by the use of forward-looking words such as "believes," "expects," "may," "will," "should," "seeks," "approximately," "intends," "plans," " ...

SEIZE THE MOMENT for a brighter future CRESCENT BIOPHARMA STRATEGIC PARTNERSHIP & PIPELINE UPDATE DECEMBER 4, 2025 NASDAQ: CBIO Disclaimers 2 Program Forward-Looking Statements Certain statements in this presentation, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, ...

STRATEGY UPDATE Capital Markets Update December 4th, 2025 AB ELECTROLUX CAPITAL MARKETS UPDATE 2025 AB ELECTROLUX CAPITAL MARKETS UPDATE 2025 Evacuation & safety information Emergency exits - Main entrance and left side of auditorium – Follow staff instructions Assembly point - Behind the office building Safety equipment - AED and first aid kit available at reception AB ELECTROLUX CAPITAL MARKETS UPDATE 2025 2 Agenda 15:00 – 15:30 Q&A 15:40 – 16:10 Brand zone tour Electrolux, AEG and Frigidare 16:15 – 17:00 ...

Financial Performance - Full Year 2025 revenue reached $2913 billion, a 14% year-over-year increase[8,70] - Full Year 2025 adjusted diluted EPS was $861, up 16% year-over-year[8,70] - Q4 2025 revenue was $7576 million, a 14% year-over-year increase[16,19] - Q4 2025 diluted EPS was $220, a 16% year-over-year increase[16,19] - The company returned over $5 billion to shareholders through dividends and share repurchases[8] Capital and Liquidity - The CET1 ratio remained stable year-over-year at 133%[8,16] - The company repurchased 35 million shares in Q4 2025, returning $13 billion to shareholders[36,41] - The Liquidity Coverage Ratio was 132%[16] Segment Performance - Canadian Personal & Business Banking revenue increased by 12% year-over-year to $3188 million in Q4 2025[44] - Canadian Commercial Banking & Wealth Management revenue increased by 15% year-over-year to $1836 million in Q4 2025[50] - U S Commercial Banking & Wealth Management revenue increased by 9% year-over-year to $584 million (US$) in Q4 2025[58] - Capital Markets revenue increased by 32% year-over-year to $1523 million in Q4 2025[64]

Company Overview - REX American is a publicly traded company on the NYSE since 1984, focusing on ethanol production and carbon capture and sequestration[8] - The company has a strong balance sheet with $3355 million in cash, cash equivalents & ST investments and $3542 million in working capital, with no bank debt[9] - REX controls approximately 300 million gallons of ethanol production annually across six facilities in the Midwest[12] Financial Performance - REX reported net sales and revenue of $1756 million, gross profit of $361 million, and net income attributable to shareholders of $071 per diluted share for Q3 2025[9] - Ethanol sales totaled 784 million gallons in Q3 2025, with an average selling price of $1731 per gallon[17] - In Q3 2025, ethanol accounted for $1357 million, representing 773% of the total product revenue[34] Carbon Capture and Sequestration (CCS) - REX is developing a carbon capture and sequestration facility at its One Earth Energy ethanol plant, expected to store approximately 560000 tons of carbon per year[46] - The One Earth Energy CCS project has a potential storage capacity of 90 million tons of carbon[49] - The company anticipates potential tax credit benefits of approximately $36 million annually from the 45Q program and $150 million annually from the 45Z program after carbon sequestration[58]

Corporate Presentation December 4, 2025 Innovation-Driven Company Globally Recognized Scientific Founders Established in 2018 to >100 Employees Broad & Diversified Product Pipeline Safe Harbor and Forward-Looking Statements This presentation and any accompanying oral commentary have been prepared by MapLight Therapeutics, Inc. ("MapLight", "we," "us," "our," the "Company", or similar terms) for informational purposes only and not for any other purpose. This presentation contains trademarks, service marks, t ...